Atlas FDA

SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System

FDA premarket approval P150003/S054 · decided 2021-01-22

Approval details

PMA number
P150003
Supplement
S054
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System
Generic name
Coronary drug-eluting stent
Applicant
Boston Scientific Corporation
Date received
2019-09-03
Decision date
2021-01-22
Days to decision
507 days
Decision code
APPR
Product code
NIQ
Advisory committee
Cardiovascular
Expedited review
No
Location
Maple Grove, MN
Statement
Approval for a new stent design for the 3.50 to 5.00 mm sizes along with modifications to the expansion balloon and manifold.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
TheraSphere 360™ Y-90 Management Platform (K262462)Boston Scientific Corporation2026-07-24
FARADRIVE™ Steerable Sheath (M004PF21M402) (K262165)Boston Scientific Corporation2026-07-24
OBSIDIO Conformable Embolic (K261488)Boston Scientific Corporation2026-07-24
WallFlex Esophageal Stent System;Agile Esophageal Over-the-Wire (OTW) Stent System (K261978)Boston Scientific Corporation2026-07-10
RIVOS™ EUS Access Device (M00553900) (K260428)Boston Scientific Corporation2026-06-17
MOSES Raydar™ (K260100)Boston Scientific Corporation2026-05-18
TruSelect™ 2.6 Microcatheter (K260771)Boston Scientific Corporation2026-05-15
Asurys Fluid Management System (K251273)Boston Scientific Corporation2026-03-27